Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Experimental intra-abdominal abscesses were produced in mice by intraperitoneal injections of Bacteroides fragilis and Escherichia coli. The therapeutic efficacy of ciprofloxacin was investigated in this mixed intra-abdominal abscess model and was compared with that of rifampicin. Treatment with ciprofloxacin at 0.2 to 20 mg/kg or rifampicin at 20 mg/kg prevented all mice from death, as compared to the 60% mortality rate observed in the vehicle-treated controls. Rifampicin concentrations at 10 and 20 mg/kg were effective in preventing abscess formation and eradicated bacterial abscess. Ciprofloxacin at all the levels tested neither reduced the incidence of abscess nor eradicated Bact. fragilis from abscesses. However, ciprofloxacin at levels of 20, 10, 5, and 1 mg/kg reduced significantly the number of E. coli cells in the abscess. The peak serum level of ciprofloxacin at the oral dose of 20 mg/kg was 0.43 mg/l which was well above the MIC values for E. coli but not for Bact. fragilis.
Fu
K P
KP
Microbiology Division, Wyeth Laboratories, Inc., Philadelphia, PA 19101.
Vince
T
T
Bloom
R
R
Gregory
F J
FJ
Hung
P P
PP
D000038:Abscess / Q000188:drug therapy* / Q000382:microbiology; D000818:Animals; D001442:Bacteroides Infections / Q000188:drug therapy*; D001441:Bacteroides fragilis / Q000187:drug effects; D002939:Ciprofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D051379:Mice; D008826:Microbial Sensitivity Tests
D002939:Ciprofloxacin